In 2013, the Biomaterials and Bioengineering Laboratory of the French National Institute for Health and Medical Research (Inserm UMR 1121), co-directed by our CSO, Dr. Philippe Lavalle, discovered the antimicrobial properties of the anti-inflammatory coatings we were working on. Between 2016 and 2018, we worked to develop our technology with the support of SATT Conectus .

In 2019, our CEO, Dr. Nihal Engin Vrana, together with 2 collaborators, Dr. Philippe Lavalle and Dr. Angela Mutschler created SPARTHA Medical and were then incubated at SEMIA. 

End of 2021, Spartha Medical obtained CIR accreditation for research and development (R&D) after scientific and technical expertise. 

Spartha has been laureate of the EIC Accelerator. This grant aims to help to deploy our innovation and start clinical evaluations. The project is called SPARTHACUS.